Litcius/Paper detail

Rapid Point-of-Care Assay by SERS Detection of SARS-CoV-2 Virus and Its Variants

Peng‐Cheng Guan, Hong Zhang, Zhiyong Li, Shanshan Xu, Miao Sun, Xianmin Tian, Zhan Ma, Jia‐Sheng Lin, Man-Man Gu, Huan Wen, Fan‐Li Zhang, Yue‐Jiao Zhang, Guangjun Yu, Chaoyong Yang, Zhanxiang Wang, Yanling Song, Jian‐Feng Li

2022Analytical Chemistry52 citationsDOI

Abstract

Addressing the spread of coronavirus disease 2019 (COVID-19) has highlighted the need for rapid, accurate, and low-cost diagnostic methods that detect specific antigens for SARS-CoV-2 infection. Tests for COVID-19 are based on reverse transcription PCR (RT-PCR), which requires laboratory services and is time-consuming. Here, by targeting the SARS-CoV-2 spike protein, we present a point-of-care SERS detection platform that specifically detects SARS-CoV-2 antigen in one step by captureing substrates and detection probes based on aptamer-specific recognition. Using the pseudovirus, without any pretreatment, the SARS-CoV-2 virus and its variants were detected by a handheld Raman spectrometer within 5 min. The limit of detection (LoD) for the pseudovirus was 124 TU μL–1 (18 fM spike protein), with a linear range of 250–10,000 TU μL–1. Moreover, this assay can specifically recognize the SARS-CoV-2 antigen without cross reacting with specific antigens of other coronaviruses or influenza A. Therefore, the platform has great potential for application in rapid point-of-care diagnostic assays for SARS-CoV-2.

Topics & Concepts

ChemistrySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)VirologyPoint of careSars virusVirusCoronavirus disease 2019 (COVID-19)2019-20 coronavirus outbreakChromatographyInfectious disease (medical specialty)OutbreakPathologyDiseaseNursingMedicineBiologyBiosensors and Analytical DetectionSARS-CoV-2 detection and testingAdvanced biosensing and bioanalysis techniques